Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was slightly extended in our own case — was refreshing and invigorating, because that oh-so-familiar routine of deadlines, calls, meetings, and the like has, of course, returned. The world, after all, keeps spinning now matter how hard you might push back. So time to fire up the coffee kettle and get cracking. As always, here are some tidbits to get you started. Hope you conquer the world today and please do keep in touch if you hear something juicy or just plain curious. …

Once again, Roche’s (RHHBY) $4.3 billion takeover of Spark Therapeutics (ONCE) has been delayed, possibly beyond the first half of the year, as regulators continue to scrutinize the deal for its effect on competition, Reuters writes. Both companies received a request for more information from the Federal Trade Commission in connection with its review. And the U.K. Competition and Markets Authority has opened an investigation. Roche wants to buy Spark for an experimental gene therapy for hemophilia A and a platform to develop other treatments for genetic diseases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy